Psilocybin for opioid addiction — what does the emerging evidence show?

Research specifically on psilocybin for opioid use disorder is in early stages. NYU has a phase 2 trial ongoing (2024-2026) examining psilocybin-assisted therapy for OUD in combination with buprenorphine maintenance. The mechanistic rationale: psilocybin may address the psychological dimension of addiction — identity, meaning, trauma — that pharmacological treatment alone doesn't reach. Early signals from small pilots are promising but the evidence base is not yet robust.

Important context: opioid use disorder has high mortality risk (overdose). The evidence base for medication-assisted treatment (MAT) — buprenorphine, methadone — is extremely strong and saves lives. Any psilocybin intervention for OUD should be understood as adjunctive to, not replacing, MAT. The NYU trial is designed this way: psilocybin sessions while patients continue buprenorphine. Do not attempt to treat OUD with psilocybin alone.

Comparison to ibogaine: ibogaine (a different psychedelic) has a longer research history for opioid detox and has shown striking results in some studies, though serious cardiovascular risks have limited its clinical development. Psilocybin has a substantially safer cardiovascular profile than ibogaine. The two work differently — ibogaine appears to directly reduce withdrawal symptoms while psilocybin likely acts primarily through psychological and meaning-making mechanisms.